<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00018642</url>
  </required_header>
  <id_info>
    <org_study_id>MHBS-042-96F</org_study_id>
    <nct_id>NCT00018642</nct_id>
  </id_info>
  <brief_title>Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder</brief_title>
  <official_title>Predicting the Optimal Pharmacotherapy for Outpatients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether a new drug for schizophrenia is&#xD;
      better for the maintenance treatment than a standard drugs currently prescribed. The new&#xD;
      medication is called quetiapine and it will be compared with a standard medication called&#xD;
      haloperidol decanoate. The study will determine if quetiapine causes fewer problems than&#xD;
      haloperidol with side effects such as stiffness and restlessness and whether it costs the VA&#xD;
      more or less to treat patients with quetiapine. In addition, blood samples will be collected&#xD;
      every three months to determine if certain chemicals in the blood can influence the outcome&#xD;
      of the subjects' illness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1997</start_date>
  <completion_date>March 2002</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol decanoate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Schizophrenia or Schizoaffective Disorder diagnosed by DSM-IV&#xD;
&#xD;
          2. Between the ages 18-60.&#xD;
&#xD;
          3. A candidate for maintenance antipsychotic therapy. This means that patients will have&#xD;
             had at least two documented episodes of acute schizophrenic illness or at least two&#xD;
             years of continuing psychotic symptoms.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Organic brain disease.&#xD;
&#xD;
          2. Mental Retardation&#xD;
&#xD;
          3. Chronic medical illness which would make antipsychotic medication inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2004</verification_date>
  <study_first_submitted>July 3, 2001</study_first_submitted>
  <study_first_submitted_qc>July 4, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 5, 2001</study_first_posted>
  <last_update_submitted>January 20, 2009</last_update_submitted>
  <last_update_submitted_qc>January 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2009</last_update_posted>
  <keyword>quetiapine</keyword>
  <keyword>haloperidol decanoate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

